<DOC>
	<DOC>NCT00521131</DOC>
	<brief_summary>Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites</brief_summary>
	<brief_title>Evaluation of Efficacy and Safety of Levocetirizine to Subjects With Perennial Allergic Rhinitis to House Dust Mites</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis, Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
	<mesh_term>Levocetirizine</mesh_term>
	<mesh_term>Cetirizine</mesh_term>
	<criteria>male or female ≥ 12 years suffering from a perennial allergic rhinitis to house dust mites for at least 2 years positive skin test or positive RadioAllergoSorbentTest for house dust mites the mean of the T4SS evaluated in the evening over the last 24 hours of the selection period was ≥ 5 seasonal allergic rhinitis likely to change significantly the symptoms of the subject an ear, nose or throat (ENT) infection during the two weeks preceding initial visit asthma requiring corticosteroid treatment atopic dermatitis or urticaria requiring an antihistamine treatment or the administration of oral or topical corticosteroids associated ENT disease</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Levocetirizine dihydrochloride</keyword>
	<keyword>Xyzal tablets</keyword>
</DOC>